Treatment patterns among men with metastatic Castration Resistant Prostate Cancer (mCRPC): Results from a European international study

Aim: We conducted this study to describe nonmetastatic castration-resistant prostate cancer (nmCRPC) patient characteristics and treatment patterns in the US, Europe and Japan. Materials & methods: Descriptive analyses were conducted using the 2015–2017 Ipsos Global Oncology Monitor Database. Results: A total of 2065 (442 in the US, 509 in Europe and 1114 in Japan) patients (median age: 74–80 years; stage III at diagnosis : 38.5%; Eastern Cooperative Oncology Group [ECOG] score ≤1: 79.4%; treated by urologist : 88.4%) were included in the analytic cohort. Luteinizing hormone-releasing hormone agonists and antiandrogens were the most commonly used first regimen treatments. With subsequent nmCRPC regimens their use decreased, while the use of chemotherapy, corticosteroids, androgen synthesis inhibitors and second-generation androgen receptor inhibitors increased. Conclusion: These data represent real-world treatment patterns in nmCRPC.

Download Full-text

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Journal of Global Oncology ◽

10.1200/jgo.18.00009 ◽

2018 ◽

pp. 1-12 ◽

Cited By ~ 1

Author(s):

Hideyuki Akaza ◽

Giuseppe Procopio ◽

Choosak Pripatnanont ◽

Gaetano Facchini ◽

Sergio Fava ◽

...

Keyword(s):

Prostate Cancer ◽

Real World ◽

Progression Free Survival ◽

Treatment Patterns ◽

Treatment Modalities ◽

Treatment Sequence ◽

Castration Resistant Prostate Cancer ◽

Free Survival ◽

Castration Resistant ◽

Previously Treated

Purpose There is a major clinical need to devise an optimal treatment sequence for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, sequencing information can be derived from large, real-world registry studies. Patients and Methods PROXIMA (Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy) is a large, global, prospective registry study evaluating real-world treatment patterns of patients with mCRPC who experience disease progression during or after docetaxel therapy. Patients were enrolled worldwide between 2011 and 2014. Treatments were determined by the treating physicians and recorded in categories of chemotherapy, hormonal therapy, targeted therapy, immunotherapy, and palliative therapy. Treatment sequencing patterns, response to treatment, and types of progression were recorded and analyzed. Progression-free survival and overall survival with different treatment modalities were analyzed using Kaplan–Meier method. Results Treatment patterns were evaluated in 903 patients. Therapy selection was influenced by region. Hormonal therapy (57.5%) and taxane chemotherapy (26.4%) were the most frequently administered first subsequent treatments after docetaxel. Tumor responses to first subsequent treatment were observed in 22.6% of evaluable patients. Overall survival and progression-free survival did not differ significantly across different treatment modalities. Conclusion Identifying an optimal treatment sequence is vital for improving the care of patients with mCRPC. The PROXIMA registry provided a representative sample of global data on real-world treatment patterns for patients with mCRPC previously treated with docetaxel. These data can be used to devise optimal therapy sequences and inform treatment decisions.

Download Full-text

PCN31 REAL-WORLD TREATMENT PATTERNS OF RADIUM-223 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER RECEIVING CARE AT A US TERTIARY ONCOLOGY CENTER

Value in Health ◽

10.1016/j.jval.2020.04.1537 ◽

2020 ◽

Vol 23 ◽

pp. S28

Author(s):

R.R. McKay ◽

R. Silver ◽

R. Bhak ◽

C. Korves ◽

W.Y. Cheng ◽

...

Keyword(s):

Prostate Cancer ◽

Real World ◽

Treatment Patterns ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Radium 223 ◽

Oncology Center

Download Full-text

Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e16503 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e16503-e16503

Author(s):

Nicholas J. Vogelzang ◽

Andrew J. Armstrong ◽

Celestia S. Higano ◽

A. Oliver Sartor ◽

Christopher Michael Pieczonka ◽

...

Keyword(s):

Prostate Cancer ◽

Treatment Patterns ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.3_suppl.241 ◽

2016 ◽

Vol 34 (3_suppl) ◽

pp. 241-241

Author(s):

Scott C Flanders ◽

Daniel W. Lin ◽

Lawrence Ivan Karsh ◽

Daniel H. Shevrin ◽

Neal D. Shore ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Clinical Outcomes ◽

Work Productivity ◽

Patient Characteristics ◽

The United States ◽

Treatment Patterns ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

241 Background: Patient care in castration-resistant prostate cancer (CRPC) is complex, with varying treatment patterns due to differences in therapies, patient characteristics, and physician practices. The impact of such patterns on clinical outcomes and quality of life (QoL) represent a contemporary medical issue. This study aims to improve the understanding of clinical outcomes and QoL of patients with CRPC and their caregivers. Methods: TRUMPET is a prospective, observational, multi-center study of patients with CRPC in the United States. Approximately 2000 patients and their caregivers (if eligible) will be enrolled over 24 months from IRB-approved urology and oncology sites. Eligible patients with CRPC include those with life expectancy of ≥ 6 months initiating the first active course of anti-cancer treatment for M0 or M1. A 48-month observation period will follow the last patient enrolled. Primary objectives are to describe longitudinal patterns of care, disease assessment methods, treatment decisions, treatment settings, physician referral patterns, and CRPC patient characteristics associated with these. Patient-reported health-related QoL (HRQoL) instruments will assess the effects of CRPC and its management on patient perception of key aspects of HRQoL. The following will be administered at baseline and follow-up: SF-12v2 Health Survey, Functional Assessment of Cancer Therapy–Prostate, Brief Pain Inventory-Short Form, and Memorial Anxiety Scale for Prostate Cancer (prostate-specific antigen anxiety subscale). In a patient sub-study, work productivity and treatment satisfaction will be described using the Work Productivity and Activity Impairment (WPAI) Questionnaire: Specific Health Problem and Service Satisfaction Scale for Cancer Care. Caregiver QoL and productivity will be captured with the Caregiver Quality of Life Index–Cancer and the Caregiver-modified WPAI Questionnaire. Results: As of August 21, 2015, 60 sites were active, with 63 patients and 39 caregivers enrolled. Conclusions: Outcomes from the TRUMPET study will describe treatment patterns, QoL, and health care resources associated with patient management in CRPC. Clinical trial information: NCT02380274.

Download Full-text

The National Radium-223 Dichloride Audit Group: Data from patients in United Kingdom oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.6_suppl.59 ◽

2020 ◽

Vol 38 (6_suppl) ◽

pp. 59-59

Author(s):

Manreet Randhawa ◽

Irene Stratton ◽

Robert J. Jones ◽

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Outcome Data ◽

Treatment Patterns ◽

Quality Data ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Radium 223 ◽

The Uk ◽

Ecog Ps

59 Background: Clinicians in 20 UK oncology centres comprise the National Radium-223 Dichloride Audit group which is evaluating treatment patterns and outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with Radium-223 dichloride (Xofigo). Methods: Pts first treated with Xofigo from September 2017 were included and demographics, treatment, clinical, biochemical and outcome data collected prospectively. Analysis was carried out using frequency tables, univariate and survival analysis. Results: We report the outcomes on the first 100 pts in 4 centres with good quality data. Median values of each characteristic including 25th and 75th percentiles are as follows: Age at diagnosis = 67 years (62-72), weight = 83.5kgs (73.6-92.8), Hb = 139g/L (118 – 136), WCC = 7.3X109/L (5.7 – 8.7), plt count = 252x109/L (208 – 290), ALP = 128U/L (96-263) and PSA = 42.1ug/L (21.5 – 125.7). A majority of pts had an ECOG PS of 0-1. The number of pts having Xofigo as 1st, 2nd, 3rd and 4th line treatment was 15, 64, 20 and 1 respectively. There was a statistically significant decline in median weight, Hb, WCC, plt count and ALP and a rise in PSA between cycle 1 and cycle 6. Thirty eight pts did not complete 6 cycles with 31 of these (82%) discontinuing due to disease progression. The prevalence of adverse events was 5% (20/100). Twenty nine pts had a skeletal event by 12 months. There was no change in the WHO analgesic score, QOL scores or ECOG PS between treatment 1 and 6. Thirty nine pts had subsequent lines of treatment with 31 of these having only 1 line of treatment. Median overall survival was 363 days (95% CI 312-426 days). Conclusions: The ongoing National Radium-223 Dichloride Audit records data from approximately 600 mCRPC pts treated across the UK in routine clinical NHS care. To our knowledge, it is the first prospective analysis of such pts and the largest in assessing treatment patterns, outcomes and quality of life data in addition to standard biochemical and clinical parameters. Further multivariate analysis will be presented and the implications of the licensing change of Xofigo will be illustrated in the final analysis.

Download Full-text